EGRX News and Press, Eagle Pharmaceuticals Inc. From 05/03/21

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Luciana (“Lu”) Borio, MD, to its Board of Directors. Dr. Borio brings more than a dozen years of high-level experience advancing major regul...

Eagle Pharmaceuticals (EGRX) announces that Treakisym ready-to-dilute ((RTD)) (bendamustine hydrochloride 120 mg/m2) liquid formulation has been approved for a new indication in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma (“r/r DLBCL...

-Eagle believes new indication could allow for a significant expansion of the overall market opportunity- -RTD and Rapid Infusion (“RI”) formulations anticipated to generate approximately $25 million of combined royalty and milestone revenue at peak- Eagle Phar...

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 first quarter financial results on Monday, May 10, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, Brian Ca...

Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate. The Summers Value Fund LP returned 17.5% net during Q1’21, outpacing the Russell 2000 Index...

European authorities' antitrust probe will likely push the company to change its marketing practices, which allegedly hindered competitors from introducing generic versions of Teva's Copaxone®. With the recent commercialization of Belrapzo®, a superior substitute for Teva's ...

Eagle Pharmaceuticals, Inc. (EGRX) Q4 2020 Earnings Conference Call March 2, 2021, 08:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - CEO Brian Cahill - CFO David Pernock - President and COO Judith Ng-Cashin - Chief Medical Officer Conference Call Participants Randall Stanicky ...

Image source: The Motley Fool. Eagle Pharmaceuticals Inc (NASDAQ: EGRX) Q4 2020 Earnings Call Mar 2, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Eagle Pharmaceuticals Inc (EGRX) Q4 2020 Earnings Call Transcript ...

Eagle Pharmaceuticals (EGRX): Q4 Non-GAAP EPS of $0.96 beats by $1.16; GAAP EPS of $0.60 beats by $2.02.Revenue of $49.9M (+3.4% Y/Y) misses by $1.96M.Press Release For further details see: Eagle Pharmaceuticals EPS beats by $1.16, misses on revenue

-- Q4 2020 net income was $0.62 per basic and $0.60 per diluted share and adjusted non-GAAP net income was $0.98 per basic and $0.96 per diluted share – -- FY 2020 net income was $0.89 per basic and $0.87 per diluted share and adjusted non-GAAP net income was $3.62 per ba...